New Zealand markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
44.37-0.01 (-0.02%)
At close: 04:00PM EST
44.35 -0.02 (-0.05%)
After hours: 07:38PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 107.26B
Enterprise value 136.47B
Trailing P/E 19.19
Forward P/E 14.10
PEG ratio (5-yr expected) 3.66
Price/sales (ttm)2.48
Price/book (mrq)5.33
Enterprise value/revenue 4.09
Enterprise value/EBITDA 12.36

Trading information

Stock price history

Beta (5Y monthly) 0.38
52-week change 316.24%
S&P500 52-week change 317.58%
52-week high 346.86
52-week low 333.53
50-day moving average 343.29
200-day moving average 340.55

Share statistics

Avg vol (3-month) 34.29M
Avg vol (10-day) 35.61M
Shares outstanding 52.52B
Implied shares outstanding 6N/A
Float 82.45B
% held by insiders 10.01%
% held by institutions 113.20%
Shares short (30 Dec 2021) 410.75M
Short ratio (30 Dec 2021) 42.96
Short % of float (30 Dec 2021) 4N/A
Short % of shares outstanding (30 Dec 2021) 40.43%
Shares short (prior month 29 Nov 2021) 411.68M

Dividends & splits

Forward annual dividend rate 42.2
Forward annual dividend yield 44.95%
Trailing annual dividend rate 30.80
Trailing annual dividend yield 31.80%
5-year average dividend yield 45.23
Payout ratio 493.50%
Dividend date 312 Jan 2022
Ex-dividend date 417 Nov 2021
Last split factor 22:1
Last split date 311 Nov 1991

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021

Profitability

Profit margin 12.94%
Operating margin (ttm)24.78%

Management effectiveness

Return on assets (ttm)6.47%
Return on equity (ttm)23.62%

Income statement

Revenue (ttm)33.33B
Revenue per share (ttm)13.34
Quarterly revenue growth (yoy)5.00%
Gross profit (ttm)23.21B
EBITDA 10.23B
Net income avi to common (ttm)4.31B
Diluted EPS (ttm)2.31
Quarterly earnings growth (yoy)-6.10%

Balance sheet

Total cash (mrq)3.51B
Total cash per share (mrq)1.4
Total debt (mrq)25.6B
Total debt/equity (mrq)117.74
Current ratio (mrq)0.81
Book value per share (mrq)6.16

Cash flow statement

Operating cash flow (ttm)8.04B
Levered free cash flow (ttm)8.77B